Risk factors for progression of aortic valve stenosis

Risk factors for progression of aortic valve stenosis - Risk factors for progression of aortic valve stenosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47413

Enrollment

250

Registered

2018-12-13

Start date

2017-12-14

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis

Interventions

Aortic valve stenosis

Cholesterol

Lipoprotein (a)

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Men and women aged between 18 and 80 years of age. - Able to provide written informed consent. - Mild to moderate aortic valve stenosis, defined as an aortic valve maximum velocity 2.0-4.0 m/sec. - Both bicuspid and tricuspid aortic valve morphology.

Exclusion criteria

Exclusion criteria: - Severe aortic valve stenosis (AVA

Design outcomes

Primary

Measure	Time frame
The main study parameter is progression of AVS over time. In addition, a number of candidate risk factors for AVS progression will be recorded, including a traditional lipid spectrum, lipoprotein(a) and a blood sample for DNA isolation.	—

Secondary

Measure	Time frame
The following parameters will be recorded for each participant: - Identifying information (name, sex, date of birth, contact details) - Anthropometric data (height, weight) - Comorbidities (hypertension, dyslipidemia, diabetes, coronary artery disease) - Medical history - Medication use - Laboratory parameters (traditional lipid spectrum, lipoprotein(a), fasting glucose, eGFR) - Echocardiography parameters: Bicuspid / tricuspid aortic valve morphology Aortic valve calcification score Stroke volume, mL Aortic valve maximum velocity, m/sec Maximum transvalvular gradient, mmHg Mean transvalvular gradient, mmHg Aortic valve area, cm2 Indexed aortic valve area, cm²/m² body surface area LV mass index, g/m² body surface area LV ejection fraction, %	—

Measure

Time frame

The following parameters will be recorded for each participant: - Identifying information (name, sex, date of birth, contact details) - Anthropometric data (height, weight) - Comorbidities (hypertension, dyslipidemia, diabetes, coronary artery disease) - Medical history - Medication use - Laboratory parameters (traditional lipid spectrum, lipoprotein(a), fasting glucose, eGFR) - Echocardiography parameters: Bicuspid / tricuspid aortic valve morphology Aortic valve calcification score Stroke volume, mL Aortic valve maximum velocity, m/sec Maximum transvalvular gradient, mmHg Mean transvalvular gradient, mmHg Aortic valve area, cm2 Indexed aortic valve area, cm²/m² body surface area LV mass index, g/m² body surface area LV ejection fraction, %

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)